Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Ltd., a small-cap pharmaceutical manufacturer specialising in active pharmaceutical ingredients (APIs), reported a disappointing Q3 FY26 performance marked by severe margin compression that overshadowed revenue growth. The company posted a net loss of ₹17.43 crores for the quarter ended December 2025, a sharp deterioration from the ₹10.52 crores profit recorded in Q2 FY26 and significantly worse than the ₹8.09 crores profit in Q3 FY25. The stock plummeted 10.10% to ₹471.20 following the results, reflecting investor concerns about the company's profitability trajectory despite a ₹1,897 crore market capitalisation.

Solara Active Pharma Sciences Ltd experienced a significant intraday decline on 6 Feb 2026, touching a low of Rs 482.2, down 8.06% from the previous close. The stock underperformed its sector and broader market indices, reflecting immediate selling pressure and heightened volatility.

Solara Active Pharma Sciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 23 December 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 06 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Solara Active Pharma Sciences Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 23 December 2025, reflecting a significant reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed below are based on the company’s current position as of 26 January 2026, providing investors with the latest comprehensive view.

Solara Active Pharma Sciences Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 23 December 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 15 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Solara Active Pharma Sciences Ltd has experienced a nuanced shift in its technical momentum, moving from a bearish to a mildly bearish stance across key indicators. Despite a modest day gain of 2.58%, the stock’s broader technical signals and relative performance against the Sensex suggest cautious investor sentiment amid mixed momentum cues.

Solara Active Pharma Sciences Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. The company’s stock price has declined to ₹561.45, down 1.59% from the previous close of ₹570.50, reflecting growing investor caution amid weakening technical signals and a downgrade in its overall mojo rating to Strong Sell.

Solara Active Pharma Sciences Ltd has experienced a nuanced shift in its technical momentum, moving from a bearish stance to a mildly bearish outlook, as reflected in recent market data and technical indicators. Despite a modest day gain of 2.24%, the stock’s broader trend remains cautious amid mixed signals from key momentum and volume indicators.

Solara Active Pharma Sciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 23 December 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 04 January 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook.

Solara Active Pharma Sciences Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. Despite a modest price change on 30 Dec 2025, the stock’s technical parameters reveal increasing downside risks, prompting a downgrade to a Strong Sell rating by MarketsMOJO.

Solara Active Pharma Sciences has experienced a notable shift in its technical momentum, reflecting a transition from a sideways trend to a mildly bearish stance. This change is underscored by a variety of technical indicators, including MACD, RSI, moving averages, and Bollinger Bands, which collectively paint a nuanced picture of the stock’s current market dynamics.

Solara Active Pharma Sciences has recently formed a Death Cross, a technical pattern where the 50-day moving average crosses below the 200-day moving average, often interpreted as a signal of potential long-term weakness and bearish momentum in the stock’s price trajectory.

Solara Active Pharma Sciences has experienced a revision in its market assessment following a detailed review of its financial performance, valuation metrics, technical indicators, and overall quality parameters. This reassessment reflects a nuanced view of the company’s current position within the Pharmaceuticals & Biotechnology sector amid challenging market conditions and evolving investor sentiment.

Solara Active Pharma Sciences has experienced a revision in market assessment reflecting nuanced changes across quality, valuation, financial trends, and technical indicators. While the pharmaceutical company’s recent financials reveal challenges, evolving technical signals and valuation metrics have prompted a fresh analytical perspective.

Solara Active Pharma Sciences has exhibited a notable shift in its technical momentum, transitioning from a sideways trend to a mildly bullish stance. This change comes amid a complex array of technical indicator signals, reflecting a nuanced market assessment for the pharmaceutical and biotechnology company.

Solara Active Pharma Sciences recorded a robust intraday surge, touching a high of Rs 613.75, reflecting a notable 11.38% rise during trading hours. This performance outpaced the Pharmaceuticals & Biotechnology sector by 10.47%, marking a significant day of activity for the stock.

Solara Active Pharma Sciences has experienced a notable shift in its technical momentum, reflecting a complex interplay of market forces within the Pharmaceuticals & Biotechnology sector. Recent evaluation adjustments reveal a transition from a mildly bearish trend to a sideways movement, underscoring a period of consolidation amid mixed technical signals.